BioSpace News Archive

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the presentation of preclinical data at the 2021 American Association for Cancer Research Virtual Annual Meeting.

Tachyon Therapeutics, Inc., a research and development biotechnology company, announced a presentation of data of the Company’s novel compound, TACH101, at the American Association for Cancer Research Annual Meeting.

Nearly a quarter of patients who received Opdivo plus chemotherapy showed no evidence of cancer cells in tissue removed during surgery vs. 2.2% of patients who received chemotherapy alone

Findings to be Presented at AACR Annual Meeting Further Demonstrate the Utility of Protein Biomarker Data to Support Physicians in Patient Management

Bicycle Therapeutics plc announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist, will be presented virtually in a “New Drugs on the Horizon” session at the American Association for Cancer Research Annual Meeting, taking place April 10-15, 2021.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, presented a data update on the safety and tolerability of twice daily administered poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations.

Zanidatamab preclinical data reveals additional differentiated mechanisms of action including unique ability to induce complement dependent cytotoxicity

IO-202, a first-in-class LILRB4 antagonist antibody, activates dendritic cells and inhibits solid tumor growth in preclinical studies

Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the presentation of four posters highlighting research across its immuno-oncology programs at the American Association for Cancer Research virtual Annual Meeting.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, presented data on SYNB1891 for the treatment of solid tumors and lymphoma during the American Association for Cancer Research annual meeting, April 10-15, 2021.